Compare Amphastar Pharmaceuticals Inc (AMPH) vs Chewy Inc (CHWY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Chewy Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Chewy Inc trades at $22.38 (market cap $9.25B). The key difference: Chewy Inc is far larger — about 10.7× Amphastar Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| AMPH | CHWY | |
|---|---|---|
Market Cap | $863.95M | $9.25B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $42.33 |
52-Week Low | $16.87 | $17.51 |
Enterprise Value | $1.26B | $9.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Chewy (CHWY) trades at $23.53, up 0.43% with a bullish technical signal supported by moving averages. The company shows strong revenue growth from $8.9B in 2022 to $11.86B in 2025, with net income turning positive at $393M. Recent earnings beat expectations in Q1 2026 with EPS of $0.43 versus $0.24 expected. Analyst consensus remains strongly bullish with 81.58% buy ratings and a $33.82 price target, representing 44% upside potential from current levels.
Chewy's outlook appears favorable with expanding veterinary services and Autoship subscription model driving recurring revenue. Key risks include competitive pressure from Amazon and Walmart, insider selling activity, and margin compression as net income margin is projected to decline to 1.98% in 2026. The stock offers growth potential but requires monitoring of execution against aggressive expansion plans.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Chewy Inc
Chewy is the largest e-commerce pet care retailer in the U.S., generating $8.9 billion in 2021 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a standalone company in 2019, after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.
Read more on CHWY →
